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CILP = cartilage intermediate-layer protein; CMP = cartilage matrix protein; COMP = cartilage oligomeric matrix protein; CS = chondroitin sulfate;
CS1/CS2 = chondroitin-sulfate-attachment regions of aggrecan; G1/G2/G3 = globular regions [of aggrecan]; IL-1 = interleukin-1; 
PRELP = proline- and arginine-rich end leucine-rich repeat protein; SLRP = small leucine-rich repeat proteoglycan.
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Introduction
The extracellular matrix of articular cartilage contains a
large variety of noncollagenous proteins. Many of these
are listed in Table 1, and while this list is by no means
exhaustive, it does include those that have been studied in
the most detail. It is impossible to give any common
feature that unites this group of molecules, as they vary
greatly in structure and function, and in some cases it is
not clear that they are even made by the chondrocytes.
Many of the molecules are proteoglycans, bearing gly-
cosaminoglycan chains, whereas others are glycoproteins
or even nonglycosylated proteins. Some of the molecules
represent degradation products of larger precursors that
accumulate because of their interaction with other matrix
components. Many of the molecules play a structural role,
whereas others may be involved in regulating cell function.
In addition, many of the molecules vary in their abundance
and structure with anatomical site or the person’s age, and
many are not unique to cartilage. The importance of many
of the molecules to cartilage function is illustrated in
Table 2, which shows their association with pathology
when they are produced in a mutant form.
Proteoglycans of the cartilage extracellular
matrix
Aggregating proteoglycans
Among the noncollagenous proteins of cartilage, aggre-
can has undoubtedly received the greatest attention,
because of its high abundance in cartilage, its close asso-
ciation with the ability of the tissue to resist compression,
and its modification in many cartilage disorders. Aggrecan
belongs to the family of aggregating proteoglycans that
form large, multimolecular complexes with hyaluronan [1].
The family also includes versican, neurocan, and brevican,
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though of these only versican has been shown to be
expressed in cartilage, and at much lower levels than aggre-
can. All the members of the family have an amino-terminal
globular domain, which is responsible for interaction with
hyaluronan, and a carboxy-terminal globular domain, which
has lectin-like homology. These features have resulted in the
family being termed hyalectans or lecticans.
Aggrecan has an additional globular domain (G2) that is
separated from the amino-terminal globular domain (G1)
by a short, interglobular domain [2]. The G2 domain is
separated from the carboxy-terminal globular domain (G3)
by a keratan sulfate attachment domain and two chon-
droitin sulfate (CS) attachment domains (CS1 and CS2).
Over 100 CS and keratan sulfate chains may be present
in the three glycosamino-glycan attachment domains,
though it is not clear at present whether all potential
attachment sites are always occupied or whether variation
may occur among individuals. The high CS and keratan
sulfate content of aggrecan and its ability to interact with
hyaluronan are essential features for normal articular
cartilage function, as they provide the rheological proper-
ties necessary for resisting compression. The function of
the G3 domain of aggrecan is unclear. Its lectin-like prop-
erties suggest the possibility of interaction with other com-
ponents of the extracellular matrix [3], though it has also
been suggested that it is involved in intracellular trafficking
during aggrecan synthesis. Mutations in the aggrecan
gene that prevent core protein synthesis form the basis of
chondrodysplasias in mice (cartilage matrix deficiency)
and chicks (nanomelia) [3]. In addition, impaired glyco-
saminoglycan sulfation on aggrecan causes the chondro-
dysplastic phenotypes associated with the brachymorphic
mouse and diastrophic dysplasia in humans.
An interesting feature of the human aggrecan gene is the
existence of polymorphism in the region encoding the
CS1 domain. This region is composed of repeat
sequences, which may range in number from 13 to 33 [4].
Individuals with the shortest alleles will have the lowest
proportion of CS on their aggrecan molecules, and may
be at risk for cartilage degeneration due to impaired
aggrecan function. Irrespective of such polymorphism, the
glycosaminoglycan composition of aggrecan varies con-
siderably during juvenile development, as both the size
and sulfation pattern of the CS and keratan sulfate
change, though the functional consequence of this
change is unclear. In addition, size heterogeneity is gener-
ated in the aggrecan core protein by the action of pro-
teinases, with those fragments bearing a G1 domain being
selectively retained in the tissue matrix. Proteolysis ulti-
mately results in the accumulation of free G1 domains that
have a long half-life in the tissue [5]. Many proteinases are
able to degrade aggrecan if they gain access to the carti-
lage matrix, but most physiological and pathological
degradation of articular cartilage is associated with the
Table 1
Proteoglycans (PGs) and proteins of the cartilage extracellular
matrix
Proteoglycans Proteins
Aggregating Structural
Aggrecan COMP (Thrombospondin-5)
Versican Thrombospondin-1 and -3
Link protein CMP (Matrilin-1)
Leucine-rich repeat Matrilin-3
Biglycan (DS-PGI) CILP
Decorin (DS-PGII) C-type lectin
Epiphycan (DS-PGIII) Fibronectin
Fibromodulin PRELP
Lumican Chondroadherin
Other Tenascin-C
Perlecan Fibrillin
SZP/Lubricin Elastin
Regulatory
gp-39/YKL-40
Matrix gla protein/ MGP
Pleiotrophin
Chondromodulin-I/SCGP
Chondromodulin-II
CD-RAP
Growth factors
Other
Chondrocalcin
PARP
Lysozyme
Phospholipase A2
Proteinases and inhibitors
CD-RAP = cartilage-derived retinoic acid responsive protein; CILP =
cartilage intermediate layer protein; CMP = cartilage matrix protein;
COMP = cartilage oligomeric matrix protein; DS-PG(I, II, III) =
dermatan sulfate proteoglycan (I, II, III); gla = gamma-carboxyglutamic
acid; gp = glycoprotein; PARP = proline- and arginine-rich protein;
PRELP = proline- and arginine-rich end leucine-rich repeat protein;
SZP = superficial zone protein.
Table 2
Genetic disorders and the mutant cartilage matrix
proteoglycans and proteins with which they are associated
Mutant matrix molecule Associated disorder1
Aggrecan (impaired core  Cartilage matrix deficiency (in mice)
protein synthesis) Nanomelia (in chickens)
Brachymorphism (in mice)
Aggrecan (impaired  Diastrophic dysplasia
glycosaminoglycan sulfation) Achondrogenesis 1B
Atelosteogenesis type II
Perlecan Chondrodystrophic myotonia
Dyssegmental dysplasia
SZP Camptodactyly–arthropathy–
coxa vara–pericarditis syndrome
COMP Pseudoachondroplasia
Multiple epiphyseal dysplasia
1Human disorder unless indicated otherwise. COMP = cartilage
oligomeric protein; SZP = superficial zone protein.Arthritis Research    Vol 3 No 6 Roughley
action of matrix metalloproteinases and aggrecanases [6].
Degradation products resulting from the action of both
classes of proteinase accumulate in the synovial fluid of
patients with arthritis [7,8] and have been used as markers
of tissue destruction. Aggrecan synthesized in the arthritic
joint has a CS sulfation pattern more akin to that in the
normal juvenile than the normal adult. The appearance of
this immature CS structure has also been used as a
marker of the arthritic joint, and in particular of the repara-
tive process that is being mounted. The G1-containing
aggrecan fragments that accumulate with age or tissue
degeneration may play a role in the induction of an autoim-
mune polyarthritis in susceptible individuals [9].
The interaction of aggrecan with hyaluronan is stabilized
by the presence of link proteins. As with aggrecan, these
proteins undergo proteolytic modification throughout life
and can be used as an indicator of proteinase action. They
provide evidence of the action of matrix metalloproteinase
throughout juvenile development, and the participation of
additional agents in the adult [10,11]. The link proteins are
not susceptible to cleavage by the aggrecanase produced
under cytokine stimulation of cartilage [12], and there is
no evidence that any of the proteolytically modified link
proteins have impaired function. Link protein can be lost
from the cartilage matrix during periods of tissue degener-
ation, but such loss is most likely due to depolymerization
of hyaluronan and involves concomitant loss of aggrecan.
The importance of link protein in proteoglycan aggregate
function is demonstrated by the impaired cartilage devel-
opment observed in the link-protein-null mouse [13].
Small leucine-rich repeat proteoglycans
The small leucine-rich repeat proteoglycans (SLRPs) are
characterized by a central domain composed of a series of
adjacent leucine-rich repeats bordered at each end by
disulfide-bonded domains [1]. The family may be divided
into two subfamilies, depending on the presence of
dermatan sulfate chains or keratan sulfate chains. Human
cartilage has been shown to contain three dermatan
sulfate proteoglycans (also called DS-PGs) – biglycan
(DS-PGI), decorin (DS-PGII), and epiphycan (DS-PGIII) –
and in all of these, the dermatan sulfate chains are in the
amino-terminal region of the core proteins. Only decorin
and biglycan have been found in articular cartilage, and
they are present throughout life. Whereas decorin remains
in its intact form at all ages, biglycan exhibits age-related
proteolytic processing that results in removal of the amino-
terminal region bearing the dermatan sulfate chains. Such
nonglycanated biglycan accumulates in the cartilage
matrix with age, but it is not clear whether this is of any
functional consequence [14]. Decorin and biglycan also
have short, amino-terminal propeptides that are removed
in the extracellular matrix by procollagen-C proteinase, the
same enzyme responsible for removing the carboxy
propeptide from type II collagen. Propeptide removal is
incomplete in adult cartilage [15], but again, the functional
consequence, if any, is unclear.
Human articular cartilage contains two potential keratan
sulfate proteoglycans, fibromodulin and lumican. Like
decorin and biglycan, fibromodulin is present in articular
cartilage throughout life, though it contains keratan sulfate
chains only in the fetus and juvenile [16]. In the adult, it
exists as a glycoprotein devoid of keratan sulfate. In con-
trast, lumican is not present in articular cartilage of the
fetus or young juvenile [17]; in the adult, it is present in
predominantly a glycoprotein form. It is unclear whether
the presence or absence of keratan sulfate influences the
function of these proteoglycans in cartilage. All SLRPs
have all been shown to interact with the fibrillar collagens
of the extracellular matrix, though their site and strength of
interaction may vary. The importance of these molecules in
matrix organization is illustrated by the abnormalities asso-
ciated with SLRP-null mice [18–21], though these abnor-
malities are perhaps less severe than might have been
expected and it is possible that there is a functional redun-
dancy between some family members. Unlike aggrecan,
the SLRPs of the cartilage matrix appear relatively resis-
tant to extensive proteolytic modification and do not show
a ready sensitivity towards cytokine-induced damage [12].
Fragments have, however, been observed in the matrix of
arthritic cartilage.
Other proteoglycans
The cartilage matrix also contains the proteoglycan per-
lecan. This is somewhat surprising, because perlecan is
commonly thought of as a basement membrane proteo-
glycan [1], yet articular cartilage is devoid of basement
membranes. Basement membrane perlecan is character-
ized by the presence of heparan sulfate chains in its
amino-terminal region, though it has been reported that
cartilage perlecan may exist in a nonglycanated form [22].
The perlecan core protein is extremely large and might be
expected to be a good candidate for proteolytic process-
ing, but at present there is no information available on
structural changes with either age or arthritis. The impor-
tance of perlecan to cartilage function is demonstrated by
the perlecan-null mouse [23], in which severe chondro-
dysplasia is a major part of the phenotype in addition to
basement membrane defects affecting heart and brain
development. In the human, mutations in the perlecan
gene have been associated with Schwartz–Jampel
syndrome (chondrodystrophic myotonia) [24], and have
recently been reported in dyssegmental dysplasia. At
present, the function of perlecan in cartilage, and in partic-
ular in the growth plates, is unknown.
A final proteoglycan associated with cartilage has been
termed superficial zone protein [25]. It is synthesized by
the superficial chondrocytes of articular cartilage and by
synoviocytes, and has an attachment site for a CS chain. Itis identical to the precursor protein of megakaryocyte-
stimulating factor, and probably is the same as a protein
originally described as lubricin, which is responsible for
the lubrication and frictionless motion of the cartilage
surface. While some superficial zone protein may be
retained in the extracellular matrix, most is destined for
secretion into the synovial cavity. The synthesis of this
protein is impaired in the arthritic joint, where alternative
splicing has been reported, and production is downregu-
lated by the presence of inflammatory cytokines such as
IL-1. Gene defects in this protein have been associated
with camptodactyly–arthropathy–coxa vara–pericarditis
syndrome [26]. In addition to its role as a lubricant, the
protein may play a role in regulating synovial cell prolifera-
tion, as this syndrome and various forms of arthritis are
associated with synovial hyperplasia. In the case of camp-
todactyly–arthropathy–coxa vara–pericarditis syndrome,
hyperplasia occurs in the absence of inflammation.
Proteins of the cartilage extracellular matrix
Structural proteins
The extracellular matrix of cartilage contains numerous
proteins that are neither collagens nor proteoglycans [27],
and several of these are thought to play a structural role in
the matrix. Cartilage oligomeric matrix protein (COMP) is
perhaps the best studied of these proteins. It belongs to
the thrombospondin family and has been termed throm-
bospondin-5, and is structurally more closely related to
thrombospondins 3 and 4 than to thrombospondins 1 and
2 [28]. Other members of the thrombospondin family have
been detected in cartilage, though not at the same level or
widespread distribution as COMP. This protein is present
in all cartilages, being most abundant in growth plate
during development, but also in mature articular cartilage.
It exists as a disulfide-bonded pentamer linked near its
amino-terminal region, and the projecting carboxy-terminal
regions are suggested to interact with collagen. The need
for COMP in cartilage is best illustrated by the presence
of pseudoachondroplasia or multiple epiphyseal dysplasia
in individuals bearing a mutation in the COMP gene [29].
A phenotype of multiple epiphyseal dysplasia can also
arise by mutations in a type IX collagen gene, and this may
indicate an association between COMP and type IX colla-
gen. During cartilage turnover, COMP undergoes degra-
dation, and fragments are released into the synovial fluid.
An increase in such fragments has been observed in the
synovial fluid of patients suffering from joint trauma and
those in the early stages of primary osteoarthritis [30], and
it has been suggested that elevated levels of COMP in
synovial fluid may serve as a marker of such disorders.
Cartilage matrix protein (CMP) is also thought to serve a
structural role in the extracellular matrix [31]. It belongs to
the matrilin family and has also been termed matrilin-1.
Matrilin-3 has also been detected in some cartilages. CMP
exists in the cartilage matrix as a disulfide-bonded trimer,
joined near the carboxy terminus of its subunits. While
CMP is present in skeletal cartilages during development,
it is most abundant in extraskeletal cartilages in the adult
and is deficient in articular cartilage. This protein is known
to interact with both type II collagen and aggrecan, though
its precise function remains unclear. Indeed, CMP-null
mice do not exhibit any obvious skeletal phenotype and
appear to develop normally [32], which may imply a func-
tional redundancy between CMP and matrilin-3. Although
CMP is not detected in normal articular cartilage, it is pro-
duced by the chondrocytes of arthritic cartilage [33].
Articular cartilages have a matrix protein that is most abun-
dant in the mid-zone of the tissue but deficient in the
deepest and superficial zones [34]. On the basis of this
localization, the protein has been termed cartilage interme-
diate-layer protein (CILP). CILP is more abundant in adult
than in juvenile articular cartilage, but the relevance of the
site- and age-related distribution to function is unknown.
CILP production has also been reported to be increased
in osteoarthritic cartilage. Interestingly, the transcript from
the CILP gene encodes two proteins. The amino-terminal
portion of the message encodes CILP, while the carboxy-
terminal portion encodes nucleotide pyrophosphohydro-
lase (NTPPHase) [35]. The initial translation product
contains both proteins, which are separated by proteolytic
cleavage within the chondrocytes. The relevance of this
phenomenon and the function of CILP are at present
unknown, and CILP does not appear to have a close
structural relationship to any other protein yet described.
Other structural proteins are thought to be involved in
cell–matrix interactions rather than matrix–matrix interac-
tions. Among these, fibronectin deserves particular
mention. Fibronectin is present in many tissues and exists
as a disulfide-bonded dimer joined at the carboxy terminus
of its subunits [36]. Fibronectin can exist in multiple iso-
forms, because of alternative splicing of its gene, and
chondrocytes appear to produce a characteristic splice
variant [37]. The abundance of fibronectin increases about
10-fold in osteoarthritic cartilage [38], though the func-
tional significance of this is unclear. However, it is interest-
ing that fibronectin fragments, resulting from proteolytic
degradation, are able to propagate degradation of aggre-
can at the same sites as expected for the action of aggre-
canase [39]. It has been suggested that the fibronectin
fragments that may accumulate in the arthritic joint may
stimulate the local production of inflammatory cytokines,
such as IL-1, that upregulate aggrecanase expression.
Another molecule of interest is proline- and arginine-rich
end leucine-rich repeat protein (PRELP), which is closely
related in protein structure and gene organization to fibro-
modulin and lumican but is devoid of keratan sulfate
chains. PRELP shows selective distribution among carti-
lagenous tissues and is not present in fetal and young
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region of PRELP may facilitate interaction with heparan
sulfate proteoglycans on cell membranes [41]. A final
protein worthy of note is chondroadherin, which bears
neither glycosaminoglycan chains nor N-linked oligosac-
charides and, in common with elastin, may be devoid of
carbohydrate. Chondroadherin also belongs to the family
of leucine-rich repeat proteins [42] and, in common with
PRELP, is thought to play a role in mediating cell–matrix
interactions.
Regulatory proteins
Several proteins in the extracellular matrix are thought to
influence cell proliferation or metabolism rather than play a
structural role in the matrix (see Table 1), but a discussion
of their properties is beyond the scope of this review.
However, one of these proteins, termed gp-39, deserves
special recognition. It is related to the chitinase family but
does not have enzymic activity. It is not detected in normal
articular cartilage, but is produced by chondrocytes in
culture and is present in arthritic cartilage [43]. As such, it
may reflect situations in which rapid tissue remodelling is
occurring and may be indicative of the capacity of chon-
drocytes to recognize an abnormal environment and initi-
ate a repair response.
Other proteins
This category includes proteinases and their inhibitors,
degradation products of collagen, and basic proteins that
associate with the extracellular matrix. Two products of
collagen degradation have been reported to accumulate in
cartilage [27]. One is chondrocalcin, which represents the
carboxy-propeptide of type II collagen, and the second is
proline–arginine-rich protein, which represents the amino-
propeptide domain of the α2(XI) chain of type XI collagen.
It is possible that these molecules are not merely innocent
bystanders but are involved in feedback regulation of col-
lagen synthesis. The abundance of chondrocalcin in carti-
lage is often used as an indication of new collagen
synthesis. Finally, lysozyme [44] and phospholipase A2
[45] are worthy of mention. Both are cationic proteins that
may owe their presence in the cartilage matrix to the high
content of anionic aggrecan. In the case of lysozyme, it is
likely that much of it is not produced by the chondrocytes
but rather is absorbed from the synovial fluid.
Conclusion
It is apparent from this brief review that the extracellular
matrix of cartilage contains many noncollagenous proteins
and proteoglycans whose precise functions are only just
beginning to be understood. These molecules may serve a
structural or regulatory role, and in some cases may do
both, as degradation products of some of the structural
molecules are known to influence the chondrocyte. The
recognition of genetic disorders in which synthesis of the
matrix molecules is perturbed has aided greatly in our
understanding of their functional role, but the reason for
many site- and age-related restrictions in expression
remains unclear. The role of many of the molecules in the
arthritic joint is also unclear, as in many cases they may be
pawns of the disease, undergoing destruction, yet in
others they may be actively involved in propagating
destruction or initiating repair. This is an area where there
is still a wealth of information to be mined.
Acknowledgement
The author is funded by the Shriners of North America.
References
1. Iozzo RV: Matrix proteoglycans: from molecular design to cel-
lular function. Annu Rev Biochem 1998, 67:609-652.
2. Watanabe H, Yamada Y, Kimata K: Roles of aggrecan, a large
chondroitin sulfate proteoglycan, in cartilage structure and
function. J Biochem 1998, 124:687-693.
3. Vertel B: The ins and outs of aggrecan. Trends Cell Biol 1995,
5:458-464.
4. Doege KJ, Coulter SN, Meek LM, Maslen K, Wood JG: A human-
specific polymorphism in the coding region of the aggrecan
gene. Variable number of tandem repeats produce a range of
core protein sizes in the general population. J Biol Chem
1997, 21:13974-13979.
5. Maroudas A, Bayliss MT, Uchitel-Kaushansky N, Schneiderman R,
Gilav E: Aggrecan turnover in human articular cartilage: use of
aspartic acid racemization as a marker of molecular age. Arch
Biochem Biophys 1998, 350:61-71.
6. Caterson B, Flannery CR, Hughes CE, Little CB: Mechanisms
involved in cartilage proteoglycan catabolism. Matrix Biol
2000, 19:333-344.
7. Lohmander LS, Neame PJ, Sandy JD: The structure of aggrecan
fragments in human synovial fluid. Evidence that aggrecanase
mediates cartilage degradation in inflammatory joint disease,
joint injury, and osteoarthritis. Arthritis Rheum 1993, 9:1214-
1222.
8. Fosang AJ, Last K, Maciewicz RA: Aggrecan is degraded by
matrix metalloproteinases in human arthritis. Evidence that
matrix metalloproteinase and aggrecanase activities can be
independent. J Clin Invest 1996, 98:2292-2299.
9. Glant TT, Cs-Szabó G, Nagase H, Jacobs JJ, Mikecz K: Progres-
sive polyarthritis induced in BALB/c mice by aggrecan from
normal and osteoarthritic human cartilage. Arthritis Rheum
1998, 41:1007-1018.
10. Nguyen Q, Liu J, Roughley PJ, Mort JS: Link protein as a monitor
in situ of endogenous proteolysis in adult human articular
cartilage. Biochem J 1991, 278:143-147.
11. Hughes CE, Caterson B, White RJ, Roughley PJ, Mort JS: Mono-
clonal antibodies recognizing protease-generated neoepi-
topes from cartilage proteoglycan degradation. Application to
studies of human link protein cleavage by stromelysin. J Biol
Chem 1992, 267:16011-16014.
12. Sztrolovics R, White RJ, Poole AR, Mort JS, Roughley PJ: Resis-
tance of small leucine-rich repeat proteoglycans to proteolytic
degradation during interleukin-1-stimulated cartilage catabo-
lism. Biochem J 1999, 339:571-577.
13. Watanabe H, Yamada Y: Mice lacking link protein develop
dwarfism and craniofacial abnormalities. Nat Genet 1999, 21:
225-229.
14. Roughley PJ, White RJ, Magny MC, Liu J, Pearce RH, Mort JS:
Non-proteoglycan forms of biglycan increase with age in
human articular cartilage. Biochem J 1993, 295:421-426.
15. Roughley PJ, White RJ, Mort JS: Presence of pro-forms of
decorin and biglycan in human articular cartilage. Biochem J
1996, 318:779-784.
16. Roughley PJ, White RJ, Cs-Szabó G, Mort JS: Changes with age
in the structure of fibromodulin in human articular cartilage.
Osteoarthritis Cart 1996, 4:153-161.
17. Grover J, Chen XN, Korenberg JR, Roughley PJ: The human
lumican gene. Organization, chromosomal location, and
expression in articular cartilage. J Biol Chem 1995,  270:
21942-21949.
Arthritis Research    Vol 3 No 6 RoughleyAvailable online http://arthritis-research.com/content/3/6/342
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
18. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE,
Iozzo RV: Targeted disruption of decorin leads to abnormal
collagen fibril morphology and skin fragility. J Cell Biol 1997,
136:729-743.
19. Xu T, Bianco P, Fisher LW, Longenecker G, Smith E, Goldstein S,
Bonadio J, Boskey A, Heegaard AM, Sommer B, Satomura K,
Dominguez P, Zhao C, Kulkarni AB, Robey PG, Young MF:
Targeted disruption of the biglycan gene leads to an osteo-
porosis-like phenotype in mice. Nat Genet 1998, 20:78-82.
20. Svensson L, Aszódi A, Reinholt FP, Fassler R, Heinegård D,
Oldberg Å: Fibromodulin-null mice have abnormal collagen
fibrils, tissue organization, and altered lumican deposition in
tendon. J Biol Chem 1999, 14:9636-9647.
21. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C,
Carroll H: Lumican regulates collagen fibril assembly: skin
fragility and corneal opacity in the absence of lumican. J Cell
Biol 1998, 141:1277-1286.
22. Iozzo RV, Cohen IR, Grassel S, Murdoch AD: The biology of per-
lecan: the multifaceted heparan sulphate proteoglycan of
basement membranes and pericellular matrices. Biochem J
1994, 302:625-639.
23. Costell M, Gustafsson E, Aszódi A, Morgelin M, Bloch W, Hun-
ziker E, Addicks K, Timpl R, Fassler R: Perlecan maintains the
integrity of cartilage and some basement membranes. J Cell
Biol 1999, 147:1109-1122.
24. Nicole S, Davoine CS, Topaloglu H, Cattolico L, Barral D,
Beighton P, Hamida C, Hammouda H, Cruaud C, White PS,
Samson D, Urtizberea JA, Lehmann-Horn F, Weissenbach J,
Hentati F, Fontaine B: Perlecan, the major proteoglycan of
basement membranes, is altered in patients with Schwartz-
Jampel syndrome (chondrodystrophic myotonia). Nat Genet
2000, 26:480-483.
25. Flannery CR, Hughes CE, Schumacher BL, Tudor D, Aydelotte
MB, Kuettner KE, Caterson B: Articular cartilage superficial
zone protein (SZP) is homologous to megakaryocyte stimu-
lating factor precursor and is a multifunctional proteoglycan
with potential growth-promoting, cytoprotective, and lubricat-
ing properties in cartilage metabolism. Biochem Biophys Res
Commun 1999, 254:535-541.
26. Marcelino J, Carpten JD, Suwairi WM, Gutierrez OM, Schwartz S,
Robbins C, Sood R, Makalowska I, Baxevanis A, Johnstone B,
Laxer RM, Zemel L, Kim CA, Herd JK, Ihle J, Williams C, Johnson
M, Raman V, Alonso LG, Brunoni D, Gerstein A, Papadopoulos N,
Bahabri SA, Trent JM, Warman ML: CACP, encoding a secreted
proteoglycan, is mutated in camptodactyly-arthropathy-coxa
vara-pericarditis syndrome. Nat Genet 1999, 23:319-322.
27. Neame PJ, Tapp H, Azizan A: Noncollagenous, nonproteoglycan
macromolecules of cartilage. Cell Mol Life Sci 1999, 55:1327-
1340.
28. Bornstein P, Sage EH: Thrombospondins. Meth Enzymol 1994,
245:62-85.
29. Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H,
Leroy JG, Mortie GR, Rimoin DL, Lachman RS, Gaines ES, Cekle-
niak JA, Knowlton RG, Cohn DH: Pseudoachondroplasia and
multiple epiphyseal dysplasia due to mutations in the carti-
lage oligomeric matrix protein gene. Nat Genet 1995, 10:330-
336.
30. Lohmander LS, Saxne T, Heinegård DK: Release of cartilage
oligomeric matrix protein (COMP) into joint fluid after knee
injury and in osteoarthritis. Ann Rheum Dis 1994, 53:8-13.
31. Jenkins RN, Osborne-Lawrence SL, Sinclair AK, Eddy RL, Byers
MG, Shows TB, Duby AD: Structure and chromosomal location
of the human gene encoding cartilage matrix protein. J Biol
Chem 1990, 265:19624-19631.
32. Aszódi A, Bateman JF, Hirsch E, Baranyi M, Hunziker EB, Hauser
N, Bösze Z, Fassler R: Normal skeletal development of mice
lacking matrilin 1: redundant function of matrilins in cartilage?
Mol Cell Biol 1999, 19:7841-7845.
33. Okimura A, Okada Y, Makihira S, Pan H, Yu L, Tanne K, Imai K,
Yamada H, Kawamoto T, Noshiro M, Yan W, Kato Y: Enhance-
ment of cartilage matrix protein synthesis in arthritic cartilage.
Arthritis Rheum 1997, 40:1029-1036.
34. Lorenzo P, Bayliss MT, Heinegård D: A novel cartilage protein
(CILP) present in the mid-zone of human articular cartilage
increases with age. J Biol Chem 1998, 273:23463-23468.
35. Lorenzo P, Neame P, Sommarin Y, Heinegård D: Cloning and
deduced amino acid sequence of a novel cartilage protein
(CILP) identifies a proform including a nucleotide pyrophos-
phohydrolase. J Biol Chem 1998, 273:23469-23475.
36. Romberger DJ: Fibronectin. Int J Biochem Cell Biol 1997, 29:
939-943.
37. Burton-Wurster N, Borden C, Lust G, Macleod JN: Expression of
the (V+C)– fibronectin isoform is tightly linked to the presence
of a cartilaginous matrix. Matrix Biol 1998, 17:193-203.
38. Brown RA, Jones KL: The synthesis and accumulation of
fibronectin by human articular cartilage. J Rheumatol 1990, 17:
65-72.
39. Homandberg GA, Davis G, Maniglia C, Shrikhande A: Cartilage
chondrolysis by fibronectin fragments causes cleavage of
aggrecan at the same site as found in osteoarthritic cartilage.
Osteoarthritis Cart 1997, 5:450-453.
40. Grover J, Chen XN, Korenberg JR, Recklies AD, Roughley PJ: The
gene organization, chromosome location, and expression of a
55-kDa matrix protein (PRELP) of human articular cartilage.
Genomics 1996, 38:109-117.
41. Bengtsson E, Aspberg A, Heinegård D, Sommarin Y, Spillmann D:
The amino-terminal part of PRELP binds to heparin and
heparan sulfate. J Biol Chem 2000, 275:40695-40702.
42. Grover J, Chen XN, Korenberg JR, Roughley PJ: The structure
and chromosome location of the human chondroadherin
gene (CHAD). Genomics 1997, 45:379-385.
43. Hakala BE, White C, Recklies AD: Human cartilage gp-39, a
major secretory product of articular chondrocytes and syn-
ovial cells, is a mammalian member of a chitinase protein
family. J Biol Chem 1993, 268:25803-25810.
44. Moss JM, Van Damme MP, Murphy WH, Stanton PG, Thomas P,
Preston BN: Purification, characterization, and biosynthesis of
bovine cartilage lysozyme isoforms. Arch Biochem Biophys
1997, 339:172-182.
45. Recklies AD, White C: Phospholipase A2 is a major compo-
nent of the salt-extractable pool of matrix proteins in adult
human articular cartilage. Arthritis Rheum 1991,  34:1106-
1115.